4 research outputs found

    Efficacy of Breast Ultrasonography for Detection of Local, Regional, and Contralateral Recurrence of Breast Cancer

    Get PDF
    Purpose: Breast uttrasonography (US) is not recommended for recurrence monitoring after breast cancer surgery due to the lack of evidence for its advantage. The purpose of this study was to evaluate the usefulness of US for detecting local recurrence (LR), regional recurrence (RR) and contralateral breast cancer (CBC) in breast cancer patients during follow-up. Methods: The medical records of 5,833 breast cancer patients who underwent breast cancer surgery between January 2003 and December 2009 were reviewed retrospectively. Physical examination (PE), mammography (MMG), and US were done routinely to detect recurrences. Detection rate for locoregional and contralateral recurrence was compared between the three modalities. Results: During the follow-up period, 125 LR, 46 RR, 83 CBC, and 29 synchronous local and regional recurrences developed in 245 patients among the study population of 5,833 breast cancer patients. Median time to recurrence was 34.7 months. The recurrence detection rate was 51.9%, 43.5%, and 90.1% for PE, MMG, and US, respectively. Mean size of the recurrent lesions detected by US (1.57 cm) was smaller than that of PE (2.69 cm) and MMG (2.03 cm) (p=0.002). Conclusion: Breast US had higher recurrence detection rate for LA, RR, and CBC than PE or MMG after breast cancer surgery. μœ λ°©μ•”μ€ 2007λ…„ μš°λ¦¬λ‚˜λΌ μ—¬μ„± μ•” λ°œμƒλ₯  2μœ„(15.1%), λ°œμƒ ν™˜μž μˆ˜λŠ” 11,606λͺ…을 μ°¨μ§€ν•˜κ³  있고, μ—°κ°„ 6,6%의 높은 λ°œμƒλ₯ μ˜ 증가λ₯Ό 보이고 μžˆλ‹€.(1) λ˜ν•œ μ§€λ‚œ 10λ…„κ°„ κ΅­λ‚΄μ˜ μœ λ°©μ•” 치료 성적도 μ§€μ†μ μœΌλ‘œ κ°œμ„ λ˜μ–΄ 5λ…„ μƒμ‘΄μœ¨μ€ 77.9%μ—μ„œ 89.5%둜 11.5% μ¦κ°€ν•˜μ˜€λ‹€. μ΄λŸ¬ν•œ μœ λ³‘λ₯ μ˜ 증가와 μž₯κΈ° μƒμ‘΄μœ¨μ˜ ν–₯μƒμœΌλ‘œ 인해 1999λ…„ 이후 9λ…„ λ™μ•ˆ μœ λ³‘μž μˆ˜λ„ 68,136λͺ…(11.2%)으둜 λΉ λ₯΄κ²Œ μ¦κ°€ν•˜κ³  μžˆλ‹€.(1,2) μ΄λŸ¬ν•œ μœ λ°©μ•” λ°œμƒλ₯  증가와 사망λ₯  κ°μ†Œ 및 μœ λ°©μ•” 수술 ν›„ μž₯κΈ°μƒμ‘΄μžμ˜ 증가에 따라 동츑 유방 λ‚΄ μž¬λ°œμ„ ν¬ν•¨ν•œ κ΅­μ†Œμž¬λ°œκ³Ό λ°˜λŒ€μΈ‘ μœ λ°©μ•”μ΄ λ°œμƒν•˜λŠ” ν™˜μžμ˜ λΉˆλ„κ°€ 졜근 μ¦κ°€ν•˜κ³  μžˆλ‹€. National Surgical Adjuvant Breast and Bowel Project(NSABP) B-06의 경우 20λ…„μ˜ 좔적 κ΄€μ°°κΈ°κ°„ λ™μ•ˆ 14.3%의 동츑 유방 재발(ipsilateral breast tumor recurrence)을 λ³΄κ³ ν•˜μ˜€κ³ ,(3) 10λ…„μ˜ 좔적 κΈ°κ°„ λ™μ•ˆ 단독 κ΅­μ†Œ-ꡬ역 재발(locoregional recurrence)은 12.4%, 4κ°œμ›” 이내 μ „μ‹ μž¬λ°œμ„ λ™λ°˜ν•œ κ΅­μ†Œ-ꡬ역 μž¬λ°œμ€ 19.8% λ³΄κ³ λ˜μ—ˆλ‹€.(4) μœ λ°©μ•”μœΌλ‘œ μΉ˜λ£Œλ°›μ€ ν™˜μžμ—μ„œ λ°˜λŒ€μΈ‘ μœ λ°©μ•”(contralateral breast cancer)이 생길 ν™•λ₯ μ€ 2-11%둜 μœ λ°©μ•”μ— 걸리지 μ•Šμ€ 여성에 λΉ„ν•΄ 2-6배의 높은 μœ„ν—˜λ„λ₯Ό 가진닀.(5) 2008λ…„ ν•œκ΅­μœ λ°©μ•”ν•™νšŒ μœ λ°©μ•” μ§„λ£ŒκΆŒκ³ μ•ˆμ„ λΉ„λ‘―ν•˜μ—¬ μ„œκ΅¬μ˜ λ‹€μ–‘ν•œ μœ λ°©μ•” μ§„λ£ŒκΆŒκ³ μ•ˆμ—μ„œλŠ” κ΅­μ†Œ, ꡬ역, 그리고 λ°˜λŒ€μΈ‘ μœ λ°©μ•” μž¬λ°œμ„ 진단함에 μžˆμ–΄μ„œ 1λ…„λ§ˆλ‹€μ˜ 좔적 κ΄€μ°°κ³Ό ν•¨κ»˜ μœ λ°©μ΄¬μ˜μˆ μ„ μ‹œν–‰ν•˜λŠ” 것을 κΆŒκ³ ν•˜κ³  μžˆλ‹€. κ·ΈλŸ¬λ‚˜ μœ λ°©μ΄ˆμŒνŒŒλ‚˜ 유방 자기곡λͺ…μ˜μƒ λ“±μ˜ 좔가적 μ˜μƒκ²€μ‚¬μ˜ νš¨μš©μ€ 아직 λΆˆν™•μ‹€ν•˜μ—¬ κ³ μœ„ν—˜ ν™˜μžμ—μ„œ μ„ νƒμ μœΌλ‘œ μ‹œν–‰ν•˜λŠ” 것을 κΆŒν•˜κ³  μžˆλ‹€.(6-11)졜근 μ—¬λŸ¬ κ΅­λ‚΄μ™Έμ˜ μ—°κ΅¬μ—μ„œ μœ λ°©μ•” 수술 ν›„ κ΅­μ†Œμž¬λ°œμ΄λ‚˜ 앑와뢀 λ¦Όν”„μ ˆ μž¬λ°œμ„ μ‘°κΈ° λ°œκ²¬ν•˜λŠ” 데 μžˆμ–΄ 유방초음파의 잠재적 νš¨μš©μ„±μ΄ 보고되고 μžˆλ‹€.(12-15) 이에 λ³Έ μ—°κ΅¬μ—μ„œλŠ” μœ λ°©μ•”μ˜ κ΅­μ†Œ, ꡬ역, 그리고 λ°˜λŒ€μΈ‘ μœ λ°©μ•” μž¬λ°œμ„ μ§„λ‹¨ν•˜λŠ” 데 μžˆμ–΄μ„œ 유방 초음파의 μœ μš©μ„±μ„ λ‹¨μΌκΈ°κ΄€μ—μ„œ μˆ˜μˆ λ°›κ³  좔적 관찰받은 ν•œκ΅­μΈ μœ λ°©μ•” ν™˜μžκ΅°μ—μ„œ λΆ„μ„ν•΄λ³΄κ³ μž ν•˜μ˜€λ‹€.λ³Έ 논문은 2010년도 μ •λΆ€(κ΅μœ‘κ³Όν•™κΈ°μˆ λΆ€)의 μž¬μ›μœΌλ‘œ ν•œκ΅­μ—°κ΅¬μž¬λ‹¨μ˜ 기초 연ꡬ사업 지원을 λ°›μ•„ μˆ˜ν–‰λœ κ²ƒμž„(2010-0004148).Kelly KM, 2010, EUR RADIOL, V20, P2557, DOI 10.1007/s00330-010-1844-1Kim HJ, 2010, ANN SURG ONCOL, V17, P2670, DOI 10.1245/s10434-010-1087-zJung KW, 2010, J KOREAN MED SCI, V25, P1113, DOI 10.3346/jkms.2010.25.8.1113Aebi S, 2010, ANN ONCOL, V21, pv9, DOI 10.1093/annonc/mdq159Lehman CD, 2009, J NATL COMPR CANC NE, V7, P1109Houssami N, 2009, ANN ONCOL, V20, P1505, DOI 10.1093/annonc/mdp037Moon HJ, 2009, RADIOLOGY, V252, P673, DOI 10.1148/radiol.2523081977Yarnold J, 2009, CLIN ONCOL-UK, V21, P159, DOI 10.1016/j.clon.2008.12.008Kim MJ, 2009, AM J ROENTGENOL, V192, P221, DOI 10.2214/AJR.07.4048Montgomery DA, 2007, BRIT J CANCER, V96, P1802, DOI 10.1038/sj.bjc.6603815Yilmaz MH, 2007, DIAGN INTERV RADIOL, V13, P13Khatcheressian JL, 2006, J CLIN ONCOL, V24, P5091, DOI 10.1200/JCO.2006.08.8575Shin JH, 2005, J ULTRAS MED, V24, P643Taghian A, 2004, J CLIN ONCOL, V22, P4247, DOI 10.1200/JCO.2004.01.042Ciatto S, 2004, EUR J CANCER, V40, P1496, DOI 10.1016/j.ejca.2004.03.010Fisher B, 2002, NEW ENGL J MED, V347, P1233KIM SH, 2000, J KOREAN RADIOL SOC, V42, P1009Chen Y, 1999, CANCER EPIDEM BIOMAR, V8, P855GORDON PB, 1995, CANCER, V76, P626GIUSEPPETTI GM, 1989, RADIOL MED, V78, P339*NAT COMPR CANC NE, NCCN CLIN PRACT GUID*AM COLL RAD, ACR BREAST IM REP DA*NAT CANC INF CTR, CANC STAT*KOR BREAST CANC S, 3 BREAST CANC MAN RE

    Pathologic correlation to internal echogenicity of breast fibroadenoma

    No full text
    μ˜ν•™κ³Ό/석사[ν•œκΈ€] μœ λ°©μ„¬μœ μ„ μ’…μ€ μ΄ˆμŒνŒŒμƒ μ „ν˜•μ μœΌλ‘œ λΆ€λ“œλŸ¬μš΄ κ²½κ³„μ˜ λ‚œμ› λ˜λŠ” μ›ν˜• μ’…κ΄΄λ‘œ κ· μΌν•œ 쀑등 λ˜λŠ” 저에코λ₯Ό 보이며 μ–‘μΈ‘μ„± 츑면꡴절음영, 얇은 경계뢀와 ν›„λ©΄μŒμ˜μ¦κ°€ λ“±μ˜ μ†Œκ²¬μ„ λ™λ°˜ν•œλ‹€. κ·ΈλŸ¬λ‚˜ μ’…κ΄΄μ˜ λͺ¨μŠ΅μ΄ λΆ„μ—½μ–‘μ΄κ±°λ‚˜ 변연이 λΆˆκ·œμΉ™ν•˜κ±°λ‚˜ κ³ μ—μ½”μ΄κ±°λ‚˜ 쀑등에코, λΆˆκ· λ“±ν•œ 내뢀에코 λ“±μ˜ λΉ„μ „ν˜•μ  ν˜•νƒœλ„ λ“œλ¬Όμ§€ μ•ŠμœΌλ©° μ΄λŸ¬ν•œ λΉ„μ „ν˜•μ  μ„¬μœ μ„ μ’…μ€ μ΄ˆμŒνŒŒμƒ μ•…μ„± μ’…κ΄΄μ™€μ˜ 감별이 μ–΄λ ΅λ‹€. μ‘°μ§λ³‘λ¦¬ν•™μ μœΌλ‘œ μ„¬μœ μ„ μ’…μ€ 기질쑰직과 μ„ μ‘°μ§μœΌλ‘œ μ΄λ£¨μ–΄μ ΈμžˆμœΌλ©° μ΄λ“€μ˜ μƒλŒ€μ  λΉ„μœ¨κ³Ό 기질쑰직의 세포밀집도에 따라 λ‹€μ–‘ν•œ ν˜•νƒœν•™μ  변이가 μžˆλ‹€. λ”°λΌμ„œ μ΄λŸ¬ν•œ 쑰직병리학적 닀양성이 λΉ„μ „ν˜•μ  초음파 μ†Œκ²¬μ˜ 원인이 될 수 μžˆμ„ 것이닀. λ³Έ μ—°κ΅¬λŠ” μœ λ°©μ„¬μœ μ„ μ’…μ™€ μ’…κ΄΄λ‚΄λΆ€ 초음파 μ†Œκ²¬κ³Ό λ³‘λ¦¬ν•™μ μ†Œκ²¬μ˜ 연관성을 μ—°κ΅¬ν•¨μœΌλ‘œμ¨ λΉ„μ „ν˜•μ  초음파 μ†Œκ²¬μ˜ 원인을 μ΄ν•΄ν•˜κ³ μž ν•˜μ˜€λ‹€. 1995λ…„ 1μ›”λΆ€ν„° 1997λ…„ 4μ›”κΉŒμ§€ λ³‘λ¦¬ν•™μ μœΌλ‘œ ν™•μ§„λœ μœ λ°©μ„¬μœ μ„ μ’… ν™˜μž 81λͺ…μ˜ 91λ³‘μ†Œλ₯Ό λŒ€μƒμœΌλ‘œ ν•˜μ˜€λ‹€. λͺ¨λ“  μ˜ˆμ—μ„œ 초음파 사진상 μ’…κ΄΄μ˜ 내뢀에 μ½” 강도, 내뢀에코 κ· λ“±μ„±, 격막 유무, μΈ‘λ©΄ ꡴절 음영, 후면에코 등을 λΆ„μ„ν•˜κ³  쑰직 μŠ¬λΌμ΄λ“œλ₯Ό κ΄€μ°°ν•˜μ—¬ μ‘°μ§ν˜•, ν˜•νƒœ, 피막 유무, 도관 ν™•μž₯ 유무, μ„νšŒν™” 유무, μ„¬μœ ν™”, μ΄ˆμžμ²΄ν™”, ν˜ˆκ΄€ 뢄포 정도λ₯Ό λΆ„μ„ν•˜μ˜€λ‹€. μ’…κ΄΄λ‚΄λΆ€ 초음파 μ†Œκ²¬κ³Ό 병리학적 μ†Œκ²¬μ˜ 각 ν•­λͺ©κ°„에 μ–΄λ– ν•œ 연관관계가 μžˆλŠ”μ§€λ₯Ό μ‚΄νŽ΄λ³΄κ³  λ‹€μŒκ³Ό 같은 κ²°κ³Όλ₯Ό μ–»μ—ˆλ‹€. 1. ν˜ˆκ΄€ 뢄포가 λ§Žμ„μˆ˜λ‘ 고에코λ₯Ό λ³΄μ˜€μœΌλ©° (p=0.006) 기질 μ„¬μœ ν™”κ°€ λ§Žμ„μˆ˜λ‘ 저에코λ₯Ό λ³΄μ˜€κ³ (p=0.035) μ΄ˆμžμ²΄ν™”κ°€ λ§Žμ„μˆ˜λ‘ 저에코λ₯Ό λ³΄μ΄λŠ” κ²½ν–₯이 μžˆμ—ˆλ‹€(p=0.087). 2. ν˜ˆκ΄€ 뢄포가 λ§Žμ„μˆ˜λ‘ λΆˆκ· λ“±ν•œ 내뢀에코λ₯Ό λ³΄μ΄λŠ” κ²½ν–₯이 μžˆμ—ˆκ³ (p=0.222) 기질 μ„¬μœ ν™”κ°€ λ§Žμ„μˆ˜λ‘ κ· λ“±ν•œ 내뢀에코λ₯Ό λ³΄μ΄λŠ” κ²½ν–₯이 μžˆμ—ˆλ‹€ (p=0.777). 3. ν˜ˆκ΄€ 뢄포가 λ§Žμ„μˆ˜λ‘ ν›„λ©΄μŒμ˜μ¦κ°•μ„ λ‚˜νƒ€λ‚΄λŠ” κ²½ν–₯이 μžˆμ—ˆμœΌλ‚˜(p=0.378) ν†΅κ³„ν•™μ μœΌλ‘œ μœ μ˜ν•˜μ§€λŠ” μ•Šμ•˜λ‹€. 4. 쒅괴내뢀에 격막이 μžˆλŠ” κ²½μš°κ°€ λ§Žμ•˜μœΌλ©°(75.5%) μ΄ˆμžμ²΄ν™”κ°€ λ§Žμ„μˆ˜λ‘ 격막이 많이 λ‚˜νƒ€λ‚¬λ‹€(p=0.049). 5. 피막이 μ—†κ±°λ‚˜ 얇은 피막이 μžˆλŠ” 경우 츑면꡴절이 λ‚˜νƒ€λ‚˜μ§€ μ•ŠλŠ” κ²½μš°κ°€ λ§Žμ•˜λ‹€. μ΄μƒμ˜ κ²°κ³Όμ—μ„œ, λ³Έ μ—°κ΅¬λŠ” 기질 μ„¬μœ ν™”λ‚˜ μ΄ˆμžμ²΄ν™”κ°€ 적은 것 λ˜λŠ” ν˜ˆκ΄€λΆ„ν¬κ°€ λ§Žμ€ 것이 λΉ„μ „ν˜•μ  μœ λ°©μ„¬μœ μ„ μ’…μ˜ 원인이 될 수 μžˆμŒμ„ μ‹œμ‚¬ν•˜μ˜€κ³  이와같은 병리학적 μ†Œκ²¬μ΄ λΉ„μ „ν˜•μ  μœ λ°©μ„¬μœ μ„ μ’…μ„ μœ λ°œν•˜λŠ” 기전에 λŒ€ν•œ 좔가적인 연ꡬ가 ν•„μš”ν•˜λ¦¬λΌ μƒκ°ν•œλ‹€. [영문] Fibroadenomas of the breast typically show smooth contour, oval or round shape, homogeneous intermediate or hypoechogenicity & they are usually associated with bilateral shadowing, thin boundary, posterior enhancement. However they often show atypical shape of lobular contour, irregular margin, hyper to intermediate internal echogenicity, heterogeneous echogenicity. It is difficult to differentiate these atypical fibroadenomas from malignant masses. Histopathologically, fibroadenomas are composed of stromal & glandular component. They vary in appearance depending on the relative amounts of glandular & stromal component and cellularity of the stroma. Therefore, the morphologic variations may be attributed to atypical sonographic findings. The purpose of this study is understanding the cause of atypical sonograpic findings by analyzing pathologic correlation to internal echogenicity of breast fibroadenoma. The material consisted of histopathologically proven 91 fibradenomas in 81 patients from January 1995 through April 1997. Sonographic interpretation was performed & descriptive criteria of mass lesions were tabulated the internal echo content (both strength and distribution), the presence of septum, the bilateral shadowing, the posterior echo pattern. A pathologist independently reviewed each case and recorded the following data : the cell type, the presence of septum, duct dilatation, calcification, fibrosis, hyalinization, vascularity. We analyzed the correlation of sonographic findings with pathologic findings and the results were as follows. 1. There was significant correlation between the increment of vascularity and the the increment of internal echo strength & between the increment of fibrosis or hyalinization and the decrement of internal echo strength. 2. The more stromal fibrosis, the more homogeneous internal echo pattern and the more vascularity, the more heterogeneous internal echo pattern are noted. 3. The more vascularity, the more posterior enhancement is noted. 4. There was a significant correlation between the increment of hyalinization and presence of septum. 5. There was a correlation between absence or thin capsule and absence of bilateral shadowing. These results suggest that the increased vascularity or the decreased stromal fibrosis or hyalinization might be the causes of atypical fibroadenoma. Further studies will be necessary on the mechanism of atypical sonographic findings based on these pathologic findings.restrictio

    Correlation of prognostic parameters and 18F-2-deoxy-D-glucose uptake in primary breast cancer

    No full text
    Dept. of Medicine/박사[ν•œκΈ€] λͺ©μ  : μœ λ°©μ•”μ€ 포도당 λŒ€μ‚¬κ°€ ν•­μ§„λ˜μ–΄ 18F-2-deoxy-D-glucose(FDG)λ₯Ό μ΄μš©ν•œ μ–‘μ „μžλ°©μΆœλ‹¨μΈ΅μ΄¬μ˜(PET)으둜 진단할 수 μžˆλ‹€. κ·ΈλŸ¬λ‚˜, μœ λ°©μ•”μ—μ„œ FDG μ„­μ·¨μœ¨μ€ 맀우 λ‹€μ–‘ν•˜κ²Œ λ‚˜νƒ€λ‚œλ‹€. λ³Έ μ—°κ΅¬μ—μ„œλŠ” ν‘œμ€€μ„­μ·¨μœ¨λ‘œ μ •λŸ‰ν™”ν•œ FDG μ„­μ·¨μœ¨κ³Ό μ—¬λŸ¬ 쑰직병리학적 μ˜ˆν›„μΈμž μ‚¬μ΄μ˜ 상관관계λ₯Ό 규λͺ…ν•˜κ³ μž ν•œλ‹€. λŒ€μƒ 및 방법 수술 μ „ 2μ£Ό 이내에 μ „μ‹  FDG-PETμ˜μƒμ„ μ΄¬μ˜ν•œ 20λͺ…μ˜ μ›λ°œμ„± μœ λ°©μ•” ν™˜μžλ₯Ό λŒ€μƒμœΌλ‘œ ν•˜μ˜€λ‹€. ν‘œμ€€μ„­μ·¨μœ¨μ€ PET μ˜μƒμ—μ„œ μ›λ°œμ’…μ–‘ μœ„μ— κ°€μž₯ μ„­μ·¨μœ¨μ΄ 높은 곳에 4 ν™”μ†Œ 크기의 μ›ν˜• κ΄€μ‹¬μ˜μ—­μ„ κ·Έλ¦° ν›„ μ΅œλŒ€κ°’μœΌλ‘œ μΈ‘μ •ν•˜μ˜€λ‹€. 20예의 μœ λ°©μ•” 쑰직을 λŒ€μƒμœΌλ‘œ μ’…μ–‘μ˜ 크기, μ•‘μ™€μž„νŒŒμ ˆ μΉ¨λ²”, 쑰직학적 μ’…λ₯˜, 쑰직학적 λ“±κΈ‰, ν•΅λ“±κΈ‰, Ki-67 λ©΄μ—­μ—Όμƒ‰μœΌλ‘œ μΈ‘μ •λ˜λŠ” μ’…μ–‘μ˜ 증식λ ₯, c-erb B-2, p53, μ—μŠ€νŠΈλ‘œκ² 수용체 μƒνƒœ, ν”„λ‘œμ œμŠ€ν…Œλ‘  수용체 μƒνƒœ, Glut-1을 λΆ„μ„ν•˜μ˜€λ‹€. FDG μ„­μ·¨μœ¨κ³Ό μ˜ˆν›„μΈμžμ™€μ˜ μƒκ΄€κ΄€κ³„λŠ” Spearman μƒκ΄€κ³„μˆ˜μ™€ Kruskal-Wallis λΉ„λͺ¨μˆ˜λ‹€μ€‘뢄석법을 μ΄μš©ν•΄μ„œ λΆ„μ„ν•˜μ˜€κ³  P값은 0.05미만일 λ•Œ μœ μ˜ν•œ κ²ƒμœΌλ‘œ κ²°μ •ν•˜μ˜€λ‹€. κ²°κ³Ό 20예의 μœ λ°©μ•”μ€ μΉ¨μœ€μ„±κ΄€μ•”μ’… 13예, μΉ¨μœ€μ„±μ†Œμ—½μƒν”Όμ•”μ’… 2예, 관상피내암쒅 1예, μˆ˜μ§ˆμ„±μ•”μ’… 1예, 점앑성암쒅 1예, 아포크린암쒅 1예, 화생성암쒅 1예 μ˜€λ‹€. Ki-67 (r=0.478, P=0.033)κ³Ό μ’…μ–‘μ˜ 크기 (r=0.589, P=0.006)κ°€ FDG μ„­μ·¨μœ¨κ³Ό ν†΅κ³„ν•™μ μœΌλ‘œ μœ μ˜ν•œ 상관관계가 μžˆμ—ˆλ‹€. κ·ΈλŸ¬λ‚˜, FDG μ„­μ·¨μœ¨κ³Ό μ•‘μ™€μž„νŒŒμ ˆ μƒνƒœ (P=0.119), 쑰직학적 μ’…λ₯˜(P=0.528), 쑰직학적 λ“±κΈ‰ (P=0.173), ν•΅λ“±κΈ‰ (P=0.149), c-erb B-2 (P=0.810), p53 (P=0.171), ER (P=0.460), PR (P=0.750) 그리고 Glut-1의 λ°œν˜„μœ¨ (강도: P=0.167, 면적: P=0.118)κ³ΌλŠ” μœ μ˜ν•œ 상관관계λ₯Ό λ³Ό 수 μ—†μ—ˆλ‹€. κ²°λ‘  μœ λ°©μ•”μ—μ„œ FDGμ„­μ·¨μœ¨μ΄ μ•‘μ™€μž„νŒŒμ ˆ μ „μ΄λ‚˜, 쑰직학적 λ“±κΈ‰, ν•΅λ“±κΈ‰, c-erb B-2, p53, ER, PRκ³Ό 같은 μ˜ˆν›„μΈμžλ“€μ˜ μƒνƒœλ₯Ό μ˜ˆμΈ‘ν•  수 μ—†μ–΄, FDG μ„­μ·¨μœ¨μ˜ 닀양성은 쑰직학적 뢄석과 면역쑰직화학염색 뢄석을 톡해 μΆ©λΆ„νžˆ μ„€λͺ…ν•  μˆ˜λŠ” μ—†μ—ˆλ‹€. κ·ΈλŸ¬λ‚˜ PETμ˜μƒμ˜ FDG μ„­μ·¨μœ¨μ€ Ki-67 λ©΄μ—­μ—Όμƒ‰μœΌλ‘œ μ •λŸ‰ν™”ν•œ 세포 증식λ ₯κ³Ό 관련이 μžˆμ—ˆλ‹€. λ”°λΌμ„œ FDG PET은 μœ λ°©μ•”μ˜ ν™œμ„±λ„μ— λŒ€ν•œ μ€‘μš”ν•œ 정보λ₯Ό μ œκ³΅ν•  수 μžˆμ—ˆλ‹€. [영문]PURPOSE : Breast cancer is characterized by increased glucose consumption and can be visualized with positron emission tomography (PET) using18F2-deoxy-2-fluoro-D-glucose (FDG). However, the FDG uptake of breast cancer varies considerably. Whether the FDG uptake, quantified as standardized uptake value (SUV), correlated with various histopathologic prognostic parameters was evaluated. MATERIALS AND METHODS Twenty patients having primary breast cancer underwent whole-body FDG-PET within 2 weeks prior to surgery. To calculate the SUV, circular region of interest (ROI) comprised of the four pixels with the highest levels of activity, was drawn over the uptake area of the primary tumor in the PET images. Twenty breast cancer specimens were analyzed for tumor size, axillary nodal involvement, histologic type, histologic grade, nuclear grade, Ki-67 immunostaining, c-erb B-2, p53, estrogen progesterone receptor (ER/PR) status and expression of the glucose transporter protein Glut-1. Correlations between the FDG uptake and prognostic parameters were determined to be significant at P<0.05 using Spearman''s correlation coefficient and Kruskal-Wallis nonparametric multiple-comparisons test. RESULTS The twenty breast cancers consisted of 13 invasive ductal, 2 invasive lobular, 1 ductal carcinoma in situ, 1 medullary, 1 mucinous, 1 apocrine, and 1 metaplastic carcinoma. Ki-67 (r=0.478, P=0.033) and tumor size (r=0.589, P=0.006) showed statistically significant positive correlations with FDG uptake. By contrast, there were no correlations between FDG uptake and axillary lymph node status (P=0.119), histologic type (P=0.528), histologic grade (P=0.173), nuclear grade (P=0.149), c-erb B-2 (P=0.810), p53 (P=0.171), ER (P=0.460), PR (P=0.750) , intensity (P=0.167) and area (P=0.118) of Glut-1 expression. CONCLUSION The FDG uptake in breast cancer could not estimate the prognostic parameters such as axillary lymph node status, histologic and nuclear grading, c-erb B-2, p53, ER, PR. Therefore, the variation in FDG uptake could not be sufficiently explained by histologic and immunohistochemical tissue analyses. However, FDG uptake during PET in breast cancer increased depending on the proliferative activity indicated by Ki-67 immunohistochemistry. The results indicate that glucose consumption in breast cancer, as determined by FDG-PET, provides valuable information about tumor activity.restrictio

    μ Šμ€ μ—¬μ„±μ˜ μœ λ°©μ— λ°œμƒν•œ μ›λ°œμ„± ν™œλ§‰ μœ‘μ’… 1예

    No full text
    ν™œλ§‰ μœ‘μ’…μ€ 주둜 κ΄€μ ˆ μ£Όμœ„ 쑰직에 ν˜Έλ°œν•˜λŠ” μ•…μ„± 쒅양이닀. μ’…μ’… κ΄€μ ˆ μ΄μ™Έμ˜ λ‹€λ₯Έ λΆ€μœ„μ— λ°œμƒν•˜λŠ” κ²½μš°λ„ λ³΄κ³ λ˜μ–΄μžˆλŠ”λ°, μ›λ°œμ„± 유방 ν™œλ§‰ μœ‘μ’…μ€ μ„Έκ³„μ μœΌλ‘œλ„ 보고된 μ˜ˆκ°€ λ“œλ¬Όλ‹€. λ³Έ μ¦λ‘€λŠ” μ›λ°œμ„± 유방 ν™œλ§‰ μœ‘μ’…μœΌλ‘œ μ§„λ‹¨λœ 15μ„Έ μ—¬μž ν™˜μžμ˜ 1μ˜ˆμ΄λ‹€. 진단 ν›„ 유방 쒅괴에 λŒ€ν•œ κ΄‘λ²”μœ„ μ ˆμ œμˆ μ„ μ‹œν–‰ν•˜μ˜€μœΌλ‚˜ 9κ°œμ›” ν›„ κ΅­μ†Œ μž¬λ°œν•˜μ˜€κ³ , 이에 재발 λΆ€μœ„μ— λŒ€ν•œ κ΄‘λ²”μœ„ μ ˆμ œμˆ μ„ λ‹€μ‹œ μ‹œν–‰ν•˜μ˜€λ‹€. κ·ΈλŸ¬λ‚˜, 27κ°œμ›” ν›„ 폐의 μš°μƒμ—½μ— 고립성 폐 전이가 λ°œκ²¬λ˜μ—ˆλ‹€. 이에 폐 병변에 λŒ€ν•œ 절제술 및 고식적 ν™”ν•™μš”λ²•μœΌλ‘œ doxorubicin 및 ifosfamide의 병합 ν™”ν•™μš”λ²•μ„ μ‹œν–‰ν•˜μ˜€λ‹€. ν˜„μž¬ ν•­μ•”ν™”ν•™μš”λ²• μ’…λ£Œ ν›„ 28κ°œμ›”μ§Έ 재발의 증거 없이 κ²½κ³Όκ΄€μ°° 쀑이닀. 이에 μ €μžλ“€μ€ λ³Έ 증둀λ₯Ό λ¬Έν—Œκ³ μ°°κ³Ό ν•¨κ»˜ λ³΄κ³ ν•˜λŠ” 바이닀
    corecore